BRCA1 in clinical breast cancer

C. Kent Osborne, Richard M Elledge, Powel H. Brown, Susan G. Hilsenbeck

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

It should be clear from this review that most, if not all, questions raised at the beginning have only partial answers at best. Significant gaps remain and must await greater understanding of the biological effects of BRCA1 and BRCA2 alterations; the natural history of molecularly defined mutation-associated breast cancer; and the effects of currently proposed prevention and treatment strategies. In this regard, pediatric oncology may provide a useful paradigm. Tremendous advances can be made, even in very rare diseases, by population-wide inclusion of at-risk individuals in standardized management protocols and rigorous collection of associated outcome data.

Original languageEnglish (US)
Pages (from-to)77-88
Number of pages12
JournalBreast Disease
Volume10
Issue number1-2
StatePublished - Apr 1998

Fingerprint

Rare Diseases
Natural History
Pediatrics
Breast Neoplasms
Mutation
Population

ASJC Scopus subject areas

  • Surgery

Cite this

Osborne, C. K., Elledge, R. M., Brown, P. H., & Hilsenbeck, S. G. (1998). BRCA1 in clinical breast cancer. Breast Disease, 10(1-2), 77-88.

BRCA1 in clinical breast cancer. / Osborne, C. Kent; Elledge, Richard M; Brown, Powel H.; Hilsenbeck, Susan G.

In: Breast Disease, Vol. 10, No. 1-2, 04.1998, p. 77-88.

Research output: Contribution to journalArticle

Osborne, CK, Elledge, RM, Brown, PH & Hilsenbeck, SG 1998, 'BRCA1 in clinical breast cancer', Breast Disease, vol. 10, no. 1-2, pp. 77-88.
Osborne CK, Elledge RM, Brown PH, Hilsenbeck SG. BRCA1 in clinical breast cancer. Breast Disease. 1998 Apr;10(1-2):77-88.
Osborne, C. Kent ; Elledge, Richard M ; Brown, Powel H. ; Hilsenbeck, Susan G. / BRCA1 in clinical breast cancer. In: Breast Disease. 1998 ; Vol. 10, No. 1-2. pp. 77-88.
@article{d09f18645e6f4644b75f931728f691c5,
title = "BRCA1 in clinical breast cancer",
abstract = "It should be clear from this review that most, if not all, questions raised at the beginning have only partial answers at best. Significant gaps remain and must await greater understanding of the biological effects of BRCA1 and BRCA2 alterations; the natural history of molecularly defined mutation-associated breast cancer; and the effects of currently proposed prevention and treatment strategies. In this regard, pediatric oncology may provide a useful paradigm. Tremendous advances can be made, even in very rare diseases, by population-wide inclusion of at-risk individuals in standardized management protocols and rigorous collection of associated outcome data.",
author = "Osborne, {C. Kent} and Elledge, {Richard M} and Brown, {Powel H.} and Hilsenbeck, {Susan G.}",
year = "1998",
month = "4",
language = "English (US)",
volume = "10",
pages = "77--88",
journal = "Breast Disease",
issn = "0888-6008",
publisher = "IOS Press",
number = "1-2",

}

TY - JOUR

T1 - BRCA1 in clinical breast cancer

AU - Osborne, C. Kent

AU - Elledge, Richard M

AU - Brown, Powel H.

AU - Hilsenbeck, Susan G.

PY - 1998/4

Y1 - 1998/4

N2 - It should be clear from this review that most, if not all, questions raised at the beginning have only partial answers at best. Significant gaps remain and must await greater understanding of the biological effects of BRCA1 and BRCA2 alterations; the natural history of molecularly defined mutation-associated breast cancer; and the effects of currently proposed prevention and treatment strategies. In this regard, pediatric oncology may provide a useful paradigm. Tremendous advances can be made, even in very rare diseases, by population-wide inclusion of at-risk individuals in standardized management protocols and rigorous collection of associated outcome data.

AB - It should be clear from this review that most, if not all, questions raised at the beginning have only partial answers at best. Significant gaps remain and must await greater understanding of the biological effects of BRCA1 and BRCA2 alterations; the natural history of molecularly defined mutation-associated breast cancer; and the effects of currently proposed prevention and treatment strategies. In this regard, pediatric oncology may provide a useful paradigm. Tremendous advances can be made, even in very rare diseases, by population-wide inclusion of at-risk individuals in standardized management protocols and rigorous collection of associated outcome data.

UR - http://www.scopus.com/inward/record.url?scp=0031897179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031897179&partnerID=8YFLogxK

M3 - Article

C2 - 15687551

AN - SCOPUS:0031897179

VL - 10

SP - 77

EP - 88

JO - Breast Disease

JF - Breast Disease

SN - 0888-6008

IS - 1-2

ER -